Personalized Cannabinoid Formulations through AI-IoT-Blockchain Synergy

Publication ID: 24-11857530_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Personalized Cannabinoid Formulations through AI-IoT-Blockchain Synergy,” Published Technical Disclosure No. 24-11857530_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857530_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,530.

Summary of the Inventive Concept

A novel system integrating AI-powered genomic analysis, IoT-connected sensors, and blockchain technology to create personalized cannabinoid formulations tailored to an individual's genotype and preferences.

Background and Problem Solved

The original patent disclosed cannabinoid formulations designed to align with an individual's genotype based on a defined list of polymorphisms. However, the existing formulations lack real-time monitoring and adjustment capabilities, and their authenticity and quality control are not ensured. The new inventive concept addresses these limitations by introducing AI-driven analysis, IoT-enabled sensors, and blockchain-based tracking to create a more powerful and effective system.

Detailed Description of the Inventive Concept

The new system comprises a genotype-based selection module utilizing AI-powered genomic analysis to identify an individual's optimal cannabinoid ratio. The formulation generation module integrates IoT-connected sensors to monitor and adjust terpene profiles in real-time. A blockchain-based tracking module ensures authenticity and quality control of the formulated product. The system can be further integrated with wearable devices, enabling real-time monitoring of physiological responses to cannabinoid formulations and machine learning-driven analysis of genotype-cannabinoid interactions.

Novelty and Inventive Step

The new claims introduce the synergistic combination of AI, IoT, and blockchain technologies, enabling real-time monitoring and adjustment of terpene profiles, and ensuring authenticity and quality control of the formulated product. This integration of distinct technologies provides a novel and non-obvious solution compared to the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different AI algorithms, IoT sensor configurations, or blockchain platforms. Variations could involve integrating additional technologies, such as augmented reality or 5G networks, to further enhance the system's capabilities.

Potential Commercial Applications and Market

The personalized cannabinoid formulation system has significant commercial potential in the cannabis and healthcare industries, offering a unique solution for tailored therapeutic experiences. The system's ability to ensure authenticity and quality control also addresses a critical need in the cannabis supply chain.

Field of Art

Pharmaceutical biotechnology, specifically cannabinoid formulation design with genomic personalization and digital health technologies

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in biotechnology, pharmacogenomics, or pharmaceutical sciences, with expertise in personalized medicine, AI-driven drug design, and digital health technologies

Obviousness Rationale

A PHOSITA would recognize that integrating AI, IoT, and blockchain technologies into personalized cannabinoid formulation represents a predictable extension of existing genomic medicine approaches. The source patent's focus on genotype-based cannabinoid design provides a clear foundation for technological augmentation using emerging digital platforms. The proposed variations represent logical combinations of known techniques in personalized medicine and digital health monitoring.

Obvious Combinations & Variations

Source Patent Element
Genotype-based cannabinoid formulation with specific cannabinoid and terpene ratios
PTD Variation
AI-powered genomic analysis module for dynamically selecting optimal cannabinoid ratios
Obviousness Reasoning
Applying machine learning to genomic data selection is a known technique in personalized medicine, representing a predictable technological progression from static genetic analysis
Source Patent Element
Cannabinoid formulation with multiple cannabinoid components
PTD Variation
IoT-connected sensors for real-time terpene profile monitoring and adjustment
Obviousness Reasoning
Integrating sensor technologies for dynamic formulation modification is a standard approach in precision medicine and pharmaceutical development
Source Patent Element
Individualized cannabinoid composition based on genetic polymorphisms
PTD Variation
Blockchain-based tracking system for ensuring formulation authenticity and quality control
Obviousness Reasoning
Implementing blockchain for supply chain and product verification is a known technique in pharmaceutical and biotechnology industries
Source Patent Element
Cannabinoid formulation with specific physiological targeting
PTD Variation
Wearable device integration for monitoring physiological responses to cannabinoid formulations
Obviousness Reasoning
Combining wearable technology with personalized medicine represents a predictable technological convergence in digital health monitoring
Source Patent Element
Genotype-based cannabinoid ratio selection
PTD Variation
Machine learning algorithms for predicting and adjusting cannabinoid interactions based on continuous physiological data
Obviousness Reasoning
Applying adaptive machine learning to personalized medicine is a standard approach for optimizing treatment protocols
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857530 and the disclosed technological variations, a person of ordinary skill in the art would find the proposed AI-IoT-blockchain enhanced cannabinoid formulation system to be an obvious combination of known techniques in personalized medicine, digital health monitoring, and pharmaceutical development. The incremental technological integrations represent predictable extensions of existing genomic medicine approaches and do not constitute a non-obvious invention.

Original Patent Information

Patent NumberUS 11,857,530
TitleCannabinoid formulations
Assignee(s)Endocanna Health, Inc.